Xyndari: Withdrawal of the marketing authorisation application


Emmaus Medical Europe Ltd withdrew its application for a marketing authorisation of Xyndari for the treatment of sickle cell disease. 

The company withdrew the application on 18 September 2019.

  • List item

    Questions and answers on the withdrawal of application for the marketing authorisation of Xyndari (glutamine) (PDF/113.42 KB)

    First published: 18/10/2019

  • Key facts

    Product number
    Date of withdrawal
    Company making the application
    Emmaus Medical Europe Ltd
    Withdrawal type
    Initial authorisation

    All documents

    Related content

    Related information on withdrawals

    A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

    An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

    How useful was this page?

    Add your rating